Patent infringement: exploitation, supply, exhaustion and exemptions

What a granted Australian patent lets its owner stop: exploiting the claimed invention under s 13 of the Patents Act 1990 (Cth), supplying products under s 117, the exhaustion of rights on sale after Calidad v Seiko Epson, the statutory exemptions, the counter-claim for revocation and the relief available.

Learning level
Core Doctrine
Jurisdictions
au-commonwealth
Subjects
intellectual-property-and-technology-law
Topics
patents

Learning outcomes

  • Apply s 13 of the Patents Act 1990 (Cth) and the definition of “exploit” to decide whether a defendant’s acts in relation to a product or method claim infringe.
  • Explain the exhaustion doctrine adopted in Calidad v Seiko Epson and distinguish permitted modification of a sold product from making a new one.
  • Work through the three limbs of s 117(2) to decide whether supplying a product infringes, using Apotex v Sanofi-Aventis.
  • Identify the statutory exemptions, the grounds of revocation available on a counter-claim and the relief and time limits that apply to infringement proceedings.

Whether an invention is patentable is one question; what a granted patent allows its owner to stop is another. The Patents Act 1990 (Cth) is Commonwealth law and states those rights for the whole of Australia. Faced with an infringement problem, a student must first ask what the defendant actually did with the claimed invention: made or sold it, used a claimed method, supplied a product that someone else used, or dealt with a product the patentee had already sold. The answer decides whether the claim rests on the exclusive rights in s 13, on the supply provision in s 117, or fails because the patentee’s rights in that product were exhausted, and only then do the exemptions and the validity counter-attack come in.

The exclusive rights: exploiting the invention

A patent gives the patentee the exclusive rights, during the term of the patent, “to exploit the invention and to authorise another person to exploit the invention” (s 13(1)).1 The patent has effect throughout the patent area (s 13(3)). The definition of exploit in Schedule 1 does most of the work:

  • for a product, to make, hire, sell or otherwise dispose of it, offer to do any of those things, use or import it, or keep it for the purpose of doing any of those things;
  • for a method or process, to use the method or process, or do any of those acts in respect of a product resulting from that use.

A person who does one of those acts in relation to the claimed invention, without the patentee’s authority, infringes. In a claim for a process for obtaining a product, s 121A can shift the onus: where the defendant alleges that it used a different process to obtain an identical product, and the court is satisfied that it is very likely the defendant’s identical product was made by the patented process, and the patentee took reasonable steps but could not find out the process actually used, the product is taken to have been made by the patented process unless the defendant proves otherwise.

After the first sale: exhaustion, repair and making

In Calidad Pty Ltd v Seiko Epson Corporation [2020] HCA 41, used Epson printer cartridges embodying the claimed inventions were modified by a third party so they could be refilled and re-used, and Calidad imported and sold them.2 Kiefel CJ, Bell and Keane JJ, with whom Gageler J agreed, held that a patentee’s rights with respect to a particular product are exhausted once that product is sold without conditions as to use, replacing the implied licence approach the Federal Court had applied (at [9], [75]). The exhaustion doctrine does not stop a patentee imposing restrictions on use after sale, but those restrictions must be obtained by negotiation and enforced under the law of contract or in equity (at [76]). Exhaustion does not reach the right to make: the question remained whether the modifications were a making of a new product. The majority held they were not: what remained were the original cartridges with modifications enabling their re-use, the modifications did not replicate parts and features of the claimed invention, and altering the cartridges in that way to prolong their life was within an owner’s rights (at [9], [69]–[70]). Whether other modifications amount to making a new embodiment of the invention remains a question of fact in each case. Nettle, Gordon and Edelman JJ, dissenting in part, would have decided the case on the making question alone and held that some categories of modified cartridge were a making of the patented invention (at [143], [266]).

Supplying a product that someone else will use

Section 117 makes a supplier an infringer where the use of the product by the person supplied would infringe the patent, unless the supplier is the patentee or licensee (s 117(1)). The relevant use is (s 117(2)):

  1. if the product is capable of only one reasonable use, having regard to its nature or design, that use;
  2. if the product is not a staple commercial product, any use the supplier had reason to believe the person would put it to;
  3. in any case, use in accordance with instructions for use, or an inducement to use, given by the supplier or contained in an advertisement published by or with the supplier’s authority.3

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50 shows how narrow those paths can be. The patent claimed a method of using leflunomide to prevent or treat psoriasis, and a majority held that a method of medical treatment can be patentable, so the patent was not invalid on that ground (French CJ at [1]).4 On infringement, Crennan and Kiefel JJ, with whom French CJ and Gageler J agreed, held that Apotex’s proposed supply of generic leflunomide did not engage s 117(2)(b) or (c). Its approved product information indicated the drug for rheumatoid and psoriatic arthritis and expressly excluded psoriasis not associated with arthritic disease, which was an emphatic instruction to use it other than in accordance with the patented method, and Apotex was not shown to have reason to believe it would be used for the patented method (at [298], [303]–[305]). Hayne J, who would have held the method not patentable, did not need to decide infringement but expressed a similar view (at [168]–[172]).

Exemptions from infringement

The Act lists acts that do not infringe. The main ones a student meets are these:

  • Prior use (s 119). For patents granted on applications filed on or after the 2006 substitution of s 119 (earlier patents remain under the former section), a person may, without infringing, exploit a product, method or process if, immediately before the priority date of the relevant claim, the person was exploiting it in the patent area or had taken definite steps to do so. The exemption is lost if, before the priority date, the person had stopped exploiting or abandoned those steps, other than temporarily, and does not apply to what the person derived from the patentee or the patentee’s predecessor in title, unless it was derived from information made publicly available by or with their consent in prescribed circumstances.
  • Regulatory approval of pharmaceuticals (s 119A). Exploiting an invention claimed in a pharmaceutical patent solely for purposes connected with obtaining inclusion in the Australian Register of Therapeutic Goods of therapeutic goods other than medical devices, or similar foreign approval, does not infringe; but exporting goods for foreign approval is covered only where the patent term has been extended and the goods meet the conditions in s 119A(2).
  • Experimental purposes (s 119C). An act done for experimental purposes relating to the subject matter of the invention does not infringe. The purposes include determining the properties of the invention, determining the scope of a claim, improving or modifying the invention, testing validity, and testing whether the patent would be infringed.5

Proceedings, the validity counter-attack and relief

Infringement proceedings may be started by the patentee or an exclusive licensee, and an exclusive licensee must join the patentee (s 120(1)–(2)). They must be started within three years from grant or six years from the infringing act, whichever ends later (s 120(4)). A defendant may counter-claim in the same proceedings for revocation of the patent (s 121), and revocation may be ordered only on the grounds in s 138(3) (revocation for lack of entitlement also requires that it be just and equitable, s 138(4)): that the patentee is not entitled to the patent, that the invention is not a patentable invention, fraud, false suggestion or misrepresentation in obtaining the patent or an amendment, or that the specification does not comply with s 40(2), (3) or (3A).6 Because the counter-claim is made in the infringement proceedings, validity and infringement can be decided together.

If infringement is established, relief includes an injunction and, at the plaintiff’s option, either damages or an account of profits (s 122(1)). The court may add an amount to damages having regard to flagrancy, deterrence, the infringer’s conduct after the infringement or after being told of it, and any benefit to the infringer (s 122(1A)). A court may refuse damages or an account of profits if the defendant proves it was not aware, and had no reason to believe, that a patent for the invention existed, but that does not affect the power to grant an injunction; and if products marked as patented in Australia had been sold or used in the patent area to a substantial extent before the infringement, the defendant is taken to have been aware of the patent unless the contrary is established (s 123).7

Applying this in a problem question

  1. Identify the claimed invention as a product or as a method, and list what the defendant did against the acts in the definition of “exploit”.
  2. If the defendant dealt with a product the patentee had sold, apply the exhaustion doctrine from Calidad, then ask whether the work done on it was a making of a new product rather than repair or modification of the old one.
  3. If the defendant only supplied a product, work through s 117(2)(a), (b) and (c) in turn, looking at the product’s possible uses, what the supplier had reason to believe and any instructions or advertising.
  4. Check each exemption against the facts, especially prior use before the priority date and experimental purposes.
  5. Consider a counter-claim for revocation on a s 138(3) ground, then select relief under ss 122 and 123, confirming the claim was brought within the s 120(4) time limit.

Pop quiz

5 quick questions on this article, the authorities it cites and the articles it links to.

  • About 3 minutes, and no time limit.
  • You can only go forwards: each answer locks when you submit it.
  • After each question you see the right answer, why, and where to read more.
  • Free, and no account needed. Log in or create a free account to keep your scores.